4D Molecular Therapeutics (FDMT) Total Current Liabilities (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Total Current Liabilities of $43.4 million for Q1 2026, up 61.36% year-over-year from $26.9 million in Q1 2025, and down 1.32% quarter-over-quarter from $44.0 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Total Current Liabilities (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Total Current Liabilities for 8 consecutive years, with $43.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 61.36% year-over-year to $43.4 million; the TTM figure through Mar 2026 stood at $43.4 million (up 61.36% YoY), while the FY2025 annual figure was $44.0 million, up 50.9% from the prior year.
- Total Current Liabilities eased to $43.4 million in Q1 2026 per FDMT's latest filing, from $44.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $44.0 million in Q4 2025 and bottomed at $11.3 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $23.4 million across 5 years, with a median of $19.0 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slipped 13.11% — and 2025, when it surged 78.72%.
- 4D Molecular Therapeutics' Total Current Liabilities stood at $15.7 million in 2022, then advanced by 20.47% to $19.0 million in 2023, then soared by 53.81% to $29.1 million in 2024, then soared by 50.9% to $44.0 million in 2025, then fell by 1.32% to $43.4 million in 2026.
- Business Quant data shows FDMT's Total Current Liabilities at $43.4 million in Q1 2026, $44.0 million in Q4 2025, and $37.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 47.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.67 Mn |
| Mar 31, 2026 | 43.40 Mn |
| Dec 31, 2025 | 43.99 Mn |
| Sep 30, 2025 | 37.11 Mn |
| Jun 30, 2025 | 34.68 Mn |
| Mar 31, 2025 | 26.90 Mn |
| Dec 31, 2024 | 29.15 Mn |
| Sep 30, 2024 | 29.47 Mn |
| Jun 30, 2024 | 19.40 Mn |
| Mar 31, 2024 | 16.40 Mn |
| Dec 31, 2023 | 18.95 Mn |
| Sep 30, 2023 | 18.16 Mn |
| Jun 30, 2023 | 13.75 Mn |
| Mar 31, 2023 | 11.28 Mn |
| Dec 31, 2022 | 15.73 Mn |
| Sep 30, 2022 | 13.56 Mn |
| Jun 30, 2022 | 14.33 Mn |
| Mar 31, 2022 | 12.09 Mn |
| Dec 31, 2021 | 16.34 Mn |
| Sep 30, 2021 | 11.37 Mn |